कृपया अन्य खोज का प्रयास करें
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Ramses M. Erdtmann | 59 | 2017 | Co-Founder, President, COO & Director |
Thomas Andrew Butler | 41 | 2017 | Co-Founder, Chairman & CEO |
Michael J. M. Hitchcock | 73 | 2021 | Independent Director |
Sumita Ray | 49 | 2021 | Independent Director |
Eric M. Aguiar | 61 | 2020 | Independent Lead Director |
Bihua Chen | 55 | 2020 | Independent Director |
David D. Smith | 53 | 2022 | Member of Scientific Advisory Board |
Rohit Kulkarni | - | - | Member of Scientific Advisory Board |
Bruce H. Lipshutz | - | 2022 | Member of Scientific Advisory Board |
Jeremy Pettus | - | 2023 | Member of Scientific Advisory Board |
Elizabeth A. Faust | 58 | 2022 | Independent Director |
Xianxin Hua | - | 2022 | Member of Scientific Advisory Board |
Margaret A. Tempero | - | 2022 | Member of Scientific Advisory Board |
David B. Ball | - | 2022 | Member of Scientific Advisory Board |
Jeffrey Rubnitz | - | 2022 | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है